cjc-1295 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-12-23. Numbers and descriptions here follow the published literature rather than marketing material.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
The theoretical underpinnings for artificial agents emerged in the mid 20th century, with establishment of cybernetics and artificial intelligence. Oliver Selfridge's 1958 "Pandemonium: A Paradigm for Learning" paper was an important early theoretical contribution in establishing agent oriented architecture. Practical implementations of agents for real world applications began to become widespread in the 1990s, after the introduction of the belief–desire–intention software model (BDI), and agent-oriented programming. Harvard professor Milind Tambe notes that in the 1990s, the definition of an AI agent was not clear. Pure digital agents were deployed in computer infrastructure for purposes such as monitoring, while agents connected to real-world sensors and actuators were increasingly used in industrial control systems. Early artificial agents tended to have simple if then logic, which expanded over time into large decision tree models. By the early 2010s, products like Siri and Alexa were released, and were sometimes called AI agents, though they lacked the general purpose reasoning ability of later agents run by large language models (LLMs). The development of LLMs during the late 2010s and early 2020s introduced new approaches to AI agents. Models such as GPT-3 demonstrated the ability to generate and understand natural language at a much larger scale than many earlier language systems. Academics began to study LLM agents from 2018.
The N‑terminal peptide is cleaved (split) from the zymogen enzyme precursor by another enzyme to release an active enzyme. The binding site of inhibitors on enzymes is most commonly the same site that binds the substrate of the enzyme. These active site inhibitors are known as orthosteric ("regular" orientation) inhibitors. The mechanism of orthosteric inhibition is simply to prevent substrate binding to the enzyme through direct competition which in turn prevents the enzyme from catalysing the conversion of substrates into products. Alternatively, the inhibitor can bind to a site remote from the enzyme active site. These are known as allosteric ("alternative" orientation) inhibitors. The mechanisms of allosteric inhibition are varied and include changing the conformation (shape) of the enzyme such that it can no longer bind substrate (kinetically indistinguishable from competitive orthosteric inhibition) or alternatively stabilise binding of substrate to the enzyme but lock the enzyme in a conformation which is no longer catalytically active.
==== Australia ==== Muscimol is considered a Schedule 9 prohibited substance in Australia under the Poisons Standard (October 2015). A Schedule 9 substance is a substance "which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities."
== The role of specific tissues and organs in transamination == Transamination takes place in several tissues and organs, especially the liver and skeletal muscle, which work together to manage amino groups generated during amino acid catabolism. The liver is the primary site of transamination. After proteins are digested into their monomers, amino acids, these amino acids are transported to the liver. In the cytoplasm of hepatocytes, the amino groups from many amino acids are transferred to α-ketoglutarate, forming glutamate in a transamination reaction. Through this process the amino groups from different amino acids are combined into glutamate, reducing the need for multiple enzymes in subsequent elimination or biosynthetic processes. After this transamination reaction, glutamate is transported into the mitochondria, where glutamate dehydrogenase catalyzes an oxidative deamination reaction, releasing ammonium. Free ammonium is toxic to cells, so the liver rapidly converts it to carbamoyl phosphate through a reaction with bicarbonate, allowing it to enter the urea cycle for excretion. The liver also contains aspartate aminotransferase. This enzyme catalyzes a unique reaction where oxaloacetate, instead of α-ketoglutarate, serves as the amino-group acceptor. In this reaction, glutamate transfers an amino group to oxaloacetate, forming the amino acid aspartate and regenerating α-ketoglutarate. Aspartate can then enter the urea cycle, where it combines with citrulline. Skeletal muscles is another site of transamination.
United States The new 323 arrived in the United States for the 1986 model year and continued to be available through 1989. The naming practice was now aligned with most of Mazda's export markets, with the 323 badge replacing GLC. For 1987 the wagon version was added to the lineup, with the same mechanicals as the hatchbacks and saloons. In 1988, Mazda added a turbocharged option in the GT and GTX model as well as four-wheel drive in the GTX model. The GTX was the first four-wheel drive passenger car Mazda offered in the United States. The GT and GTX featured a turbocharged and intercooled 1.6 liter 16-valve DOHC 4-cylinder engine rated at 132 hp (98 kW) and only was available with a 5-speed manual transmission.
Sources: en.wikipedia.org
Some manufacturers are also trying to improve on the traditional design by altering properties within these machines other than the pressure driving the sample through the orifice. One such example is Constant Systems, who have recently shown that their Cell Disruptors not only match the performance of a traditional French Press, but also that they are striving towards attaining the same results at a much lower power. Pressure Cycling Technology ("PCT"). PCT is a patented, enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels (up to 90,000 psi) to safely, conveniently and reproducibly control the actions of molecules in biological samples, e.g., the rupture (lysis) of cells and tissues from human, animal, plant, and microbial sources, and the inactivation of pathogens. PCT-enhanced systems (instruments and consumables) address some challenging problems inherent in biological sample preparation. PCT advantages include: (a) extraction and recovery of more membrane proteins, (b) enhanced protein digestion, (c) differential lysis in a mixed sample base, (d) pathogen inactivation, (e) increased DNA detection, and (f) exquisite sample preparation process control. The Microfluidizer method used for cell disruption strongly influences the physicochemical properties of the lysed cell suspension, such as particle size, viscosity, protein yield and enzyme activity.
In September 2020, an in vitro and in vivo study found that DMT present in the ayahuasca infusion promotes neurogenesis. DMT has been found to be a psychoplastogen, a compound capable of promoting rapid and sustained neuroplasticity that may have wide-ranging therapeutic benefit. The cryo-EM structures of the serotonin 5-HT2A receptor with DMT, as well as with various other psychedelics and serotonin 5-HT2A receptor agonists, have been solved and published by Bryan L. Roth and colleagues.
Narrated by Piers Gibbon, produced by Simon Nasht, directed by Chris Durlacher, made by Pilot Productions, with WGBH Nova and Rai 3 (Rai Tre) of Italy, and AVRO (AVROTROS since 2014) of the Netherlands 26 April Sweden, Sex and the Disappearing Doctors, about compulsory sterilisation in Sweden, after a law was passed in 1934; until 1975, the Swedish government had compulsory sterilised 60,000 citizens; the forty-year programme began as a eugenics programme to breed a Nordic race; historian Gunnar Broberg; environment minister Anna Lindh; writer Jan Myrdal; individuals who were unlikely to financially contribute to the Swedish state, not intelligent, or who had been labelled as anti-social, were most likely to be forcibly sterilised; anti-social youths were given the choice between being sterilised or prison; 90% of people sterilised were women, and many were single mothers of limited means; oral contraceptives made the sterilisation programme redundant; the State Institute for Racial Biology in Uppsala, and geneticist Ulf Pettersson; the documentary was conducted in a hard-hitting confrontational Panorama-style.
=== Shark repellent === P. marmoratas and P. pavoninus release pardaxin when threatened by sharks. Pardaxin targets the gills and pharyngeal cavity of the sharks. It results in severe struggling, mouth paralysis, and temporary increase of urea leakage in the gills. This distress is caused by the attack of the cellular membrane of the gills, which causes a large influx of salt ions. Research into creating a commercial shark repellent using pardaxin was discontinued because it dilutes in the water too quickly. It is only effective if sprayed almost directly into a shark's mouth.
Sources: en.wikipedia.org
=== Etymology === The word "glaucoma" comes from the Ancient Greek γλαύκωμα, a derivative of γλαυκός (glaukos), which commonly described the color of eyes which were not dark (i.e. blue, green, light gray). Eyes described as γλαυκός due to disease might have had a gray cataract in the Hippocratic era, or, in the early Common Era, the greenish pupillary hue sometimes seen in angle-closure glaucoma. This colour is reflected in the Chinese word for glaucoma, 青光眼 (qīngguāngyǎn), literally "cyan-light eye". An alternative hypothesis connects the name to the Ancient Greek noun for 'owl', γλαύξ or γλαῦξ (both glaux).
=== Biosynthesis === HMB is synthesized in the human body through the metabolism of L-leucine, a branched-chain amino acid. In healthy individuals, approximately 60% of dietary L-leucine is metabolized after several hours, with roughly 5% (2–10% range) of dietary L-leucine being converted to HMB.
In retaliation to Fanfani's indifference, the regional deputies from Reggio Calabria (5 Christian Democrats and 1 Socialist), deserted the regional council meeting scheduled for July 13, as opposed to the Communist representatives, who went instead.
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.